drugset
drugset / Trial / NCT07378865

Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants

NCT07378865 ↗

Phase 1 Recruiting 12 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ) and its active metabolite in breast milk of lactating female participants. In addition, the purpose is also to evaluate the relative infant dose (RID), safety and tolerability of SUZ and its active metabolite in lactating female participants.

Timeline

Start
2026-02-13
Primary completion
2027-02-26
Completion
2027-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Suzetrigine Small molecule — Oral

Indications

No indication recorded.